File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis

TitleElevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2007
PublisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
Citation
Journal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229 How to Cite?
AbstractObjective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud's phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; > 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 ± 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.
Persistent Identifierhttp://hdl.handle.net/10722/91501
ISSN
2014 Impact Factor: 3.187
2014 SCImago Journal Rankings: 1.040
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMok, MYen_HK
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorLo, Yen_HK
dc.contributor.authorLeung, RYHen_HK
dc.contributor.authorWong, WSen_HK
dc.contributor.authorLau, CSen_HK
dc.date.accessioned2010-09-17T10:20:25Z-
dc.date.available2010-09-17T10:20:25Z-
dc.date.issued2007en_HK
dc.identifier.citationJournal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229en_HK
dc.identifier.issn0315-162Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/91501-
dc.description.abstractObjective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud's phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; > 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 ± 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.en_HK
dc.languageengen_HK
dc.publisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.comen_HK
dc.relation.ispartofJournal of Rheumatologyen_HK
dc.subjectChemicals And Cas Registry Numbersen_HK
dc.subject.meshAdrenomedullin - blooden_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshCase-Control Studiesen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypertension, Pulmonary - blood - etiologyen_HK
dc.subject.meshLung Diseases, Interstitial - blood - etiologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRaynaud Disease - blood - etiologyen_HK
dc.subject.meshScleroderma, Systemic - blood - complications - physiopathologyen_HK
dc.titleElevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosisen_HK
dc.typeArticleen_HK
dc.identifier.emailMok, MY:temy@hkucc.hku.hken_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.authorityMok, MY=rp00490en_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid17937467en_HK
dc.identifier.scopuseid_2-s2.0-35948991493en_HK
dc.identifier.hkuros148448-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-35948991493&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume34en_HK
dc.identifier.issue11en_HK
dc.identifier.spage2224en_HK
dc.identifier.epage2229en_HK
dc.identifier.isiWOS:000250764000018-
dc.publisher.placeCanadaen_HK
dc.identifier.scopusauthoridMok, MY=7006024184en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridLo, Y=35148230000en_HK
dc.identifier.scopusauthoridLeung, RYH=7101876102en_HK
dc.identifier.scopusauthoridWong, WS=8737892100en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats